Literature DB >> 34212341

Sulfonamide Hypersensitivity.

Timothy G Chow1, David A Khan2.   

Abstract

Sulfonamides, particularly antimicrobial sulfonamides, have been implicated as a common cause of a spectrum of hypersensitivity reactions. Immediate IgE-mediated reactions have been reported but are much less common than delayed cutaneous reactions. Delayed cutaneous reactions range from benign exanthems to severe cutaneous reactions such as Stevens Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms. Sulfonamides can be subclassified as antimicrobial sulfonamides and non-antimicrobial sulfonamides, which are also distinguished by key structural differences, resulting in very low risk of cross-reactivity between these two subclasses. Immediate and delayed skin testing and in vitro testing remain limited as options in evaluating antimicrobial sulfonamide hypersensitivity. Drug challenges continue to play an important role in the evaluation of both immediate and delayed reactions, with a growing body of evidence for the safety of direct challenges regardless of human immunodeficiency virus infection status. While numerous "desensitization" protocols have been described for the management of antimicrobial sulfonamide hypersensitivity, there is limited evidence that such procedures are successful because of an induction of tolerance.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Allergy; Desensitization; Hypersensitivity; Severe cutaneous adverse reaction; Sulfonamide; Trimethoprim-sulfamethoxazole

Mesh:

Substances:

Year:  2021        PMID: 34212341     DOI: 10.1007/s12016-021-08872-3

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  85 in total

1.  The sulfonamides.

Authors:  L S COHEN; L E CLUFF
Journal:  Am J Nurs       Date:  1961-06       Impact factor: 2.220

2.  Serum sickness-like reactions to amoxicillin, cefaclor, cephalexin, and trimethoprim-sulfamethoxazole.

Authors:  R Platt; M W Dreis; D L Kennedy; J N Kuritsky
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

3.  Sulfapyridine-induced serum-sickness-like syndrome associated with plasmacytosis, lymphocytosis and multiclonal gamma-globulinopathy.

Authors:  T Han; P L Chawla; J E Sokal
Journal:  N Engl J Med       Date:  1969-03-06       Impact factor: 91.245

4.  Drug allergies documented in electronic health records of a large healthcare system.

Authors:  L Zhou; N Dhopeshwarkar; K G Blumenthal; F Goss; M Topaz; S P Slight; D W Bates
Journal:  Allergy       Date:  2016-04-06       Impact factor: 13.146

Review 5.  Sulfonamide Hypersensitivity: Fact and Fiction.

Authors:  David A Khan; Sandra R Knowles; Neil H Shear
Journal:  J Allergy Clin Immunol Pract       Date:  2019 Sep - Oct

6.  Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole.

Authors:  D G Harle; B A Baldo; J V Wells
Journal:  Mol Immunol       Date:  1988-12       Impact factor: 4.407

Review 7.  Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group.

Authors:  Carolyn C Brackett; Harleen Singh; John H Block
Journal:  Pharmacotherapy       Date:  2004-07       Impact factor: 4.705

8.  Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex.

Authors:  B R Curtis; J G McFarland; G G Wu; G P Visentin; R H Aster
Journal:  Blood       Date:  1994-07-01       Impact factor: 22.113

9.  Studies of human IgE to a sulfonamide determinant.

Authors:  D M Carrington; H S Earl; T J Sullivan
Journal:  J Allergy Clin Immunol       Date:  1987-03       Impact factor: 10.793

Review 10.  Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy.

Authors:  S Knowles; L Shapiro; N H Shear
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

View more
  1 in total

Review 1.  Drug Allergy Delabeling Programs: Recent Strategies and Targeted Populations.

Authors:  Karen M Anstey; Lulu Tsao; Iris M Otani
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-15       Impact factor: 8.667

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.